Literature DB >> 7334812

The determination of labetalol in plasma by high-performance liquid chromatography using fluorescence detection.

P A Meredith, D McSharry, H L Elliott, J L Reid.   

Abstract

A sensitive and specific assay for labetalol is described. The method employed is reverse phase high-performance liquid chromatography (HPLC) with fluorescence detection. Using 1 ml of plasma, the limit of detection of the assay was 8 ng/ml and the coefficient of variation over a typical calibration range is 5.5%. Various drugs that might be coadministered with labetalol are shown not to interfere in the assay. The method has been employed to study the pharmacokinetics of labetalol following intravenous and oral administration.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7334812     DOI: 10.1016/0160-5402(81)90070-x

Source DB:  PubMed          Journal:  J Pharmacol Methods        ISSN: 0160-5402


  4 in total

1.  Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol.

Authors:  H L Elliott; P A Meredith; D J Sumner; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1984-05       Impact factor: 4.335

2.  Comparison of medroxalol and labetalol, drugs with combined alpha- and beta-adrenoceptor antagonist properties.

Authors:  H L Elliott; K McLean; P A Meredith; D J Sumner; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1984-05       Impact factor: 4.335

3.  "Third drug" trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic.

Authors:  D McAreavey; L E Ramsey; L Latham; A D McLaren; A R Lorimer; J L Reid; J I Robertson; M P Robertson; R J Weir
Journal:  Br Med J (Clin Res Ed)       Date:  1984-01-14

4.  Labetalol disposition and concentration-effect relationships during pregnancy.

Authors:  P C Rubin; L Butters; A W Kelman; C Fitzsimons; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.